These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

959 related articles for article (PubMed ID: 29460705)

  • 21. Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Noel-Savina E; Sanchez O; Descourt R; André M; Leroyer C; Meyer G; Couturaud F
    Thromb Res; 2015 Jan; 135(1):78-83. PubMed ID: 25466839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients.
    Lee AY
    Curr Opin Pulm Med; 2003 Sep; 9(5):351-5. PubMed ID: 12904702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines.
    Rojas-Hernandez CM
    Support Care Cancer; 2018 Mar; 26(3):711-720. PubMed ID: 29188376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of direct oral anticoagulants for venous thromboembolism and stroke prophylaxis in patients with hematologic malignancies.
    Kim S; Namba J; Goodman AM; Nguyen T; Saunders IM
    J Oncol Pharm Pract; 2020 Mar; 26(2):351-360. PubMed ID: 31142232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice.
    van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV
    J Thromb Haemost; 2017 Jan; 15(1):74-79. PubMed ID: 28012224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants.
    Carrier M; Soff G; Le Gal G
    Cancer Treat Res; 2019; 179():103-115. PubMed ID: 31317483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
    Chai-Adisaksopha C; Linkins LA; ALKindi SY; Cheah M; Crowther MA; Iorio A
    Thromb Haemost; 2017 Feb; 117(3):589-594. PubMed ID: 28078351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention and treatment of cancer-associated thrombosis.
    Ng S; Carrier M
    Curr Oncol; 2020 Oct; 27(5):275-278. PubMed ID: 33173380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
    Goodin S
    Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.
    Douketis JD; Foster GA; Crowther MA; Prins MH; Ginsberg JS
    Arch Intern Med; 2000 Dec 11-25; 160(22):3431-6. PubMed ID: 11112236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on diagnosis and anticoagulant therapy for venous thromboembolism.
    Stevens H; Tran H
    Intern Med J; 2018 Oct; 48(10):1175-1184. PubMed ID: 30288893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials.
    Frere C; Farge D; Schrag D; Prata PH; Connors JM
    J Hematol Oncol; 2022 May; 15(1):69. PubMed ID: 35598026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are direct oral anticoagulants an economically attractive alternative to low molecular weight heparins in lung cancer associated venous thromboembolism management?
    Howlett J; Benzenine E; Fagnoni P; Quantin C
    J Thromb Thrombolysis; 2020 Oct; 50(3):642-651. PubMed ID: 32020515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
    Thachil J
    Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duration of anticoagulation therapy for venous thromboembolism.
    Bounameaux H; Perrier A
    Hematology Am Soc Hematol Educ Program; 2008; ():252-8. PubMed ID: 19074092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.